Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 2Phase 2 1

Status

Completed 4Terminated 2Withdrawn 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Dermatologic 1

Conditions

Multiple Myeloma 1Melanoma 1

Interventions

pembrolizumab 73Carboplatin 60Cyclophosphamide 59Nivolumab 52Paclitaxel 47Gemcitabine 44Cisplatin 43Dexamethasone 41Radiotherapy 36Rituximab 32Capecitabine 32Bevacizumab 29Docetaxel 28fludarabine 27atezolizumab 26Cytarabine 26avelumab 24Trastuzumab 23Oxaliplatin 23Lenalidomide 23Cetuximab 23venetoclax 22Ipilimumab 22Fluorouracil 22Azacitidine 22Temozolomide 21130-nm albumin-bound paclitaxel 21fludarabine phosphate 20Filgrastim 20Bortezomib 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × obatoclax × Clear all
NCT00724841 2016-07-22

A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 1/2 Terminated
1 enrolled
Dermatologic

Melanoma

NCT00719901 2015-01-12

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 1/2 Terminated
11 enrolled 9 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡